公开(公告)号：US20190010230A1

公开(公告)日：2019-01-10

申请号：US16138761

申请日：2018-09-21

Applicant: Alector LLC

Inventor： Kate MONROE ,  Tina SCHWABE ,  Francesca AVOGADRI-CONNORS ,  Ilaria TASSI ,  Helen LAM ,  Arnon ROSENTHAL

IPC: C07K16/28 ,  A61K39/00

Abstract: The invention is generally directed to methods and compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 and/or human TREM2. The methods provided herein find use in preventing, reducing risk, or treating an individual having dementia, frontotemporal dementia, Alzheimer's disease, Nasu-Hakola disease, or multiple sclerosis.

公开(公告)号：US20170240631A1

公开(公告)日：2017-08-24

申请号：US15502766

申请日：2015-08-08

Applicant: ALECTOR LLC

Inventor： Kate MONROE ,  Tina SCHWABE ,  Francesca AVOGADRI-CONNORS ,  IIaria TASSI ,  Helen LAM ,  Arnon ROSENTHAL

IPC: C07K16/28

CPC classification number: C07K16/2803 ,  A61K2039/505 ,  C07K16/28 ,  C07K16/283 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92

Abstract: The invention is generally directed to methods and compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 and/or human TREM2. The methods provided herein find use in preventing, reducing risk, or treating an individual having dementia, frontotemporal dementia, Alzheimer's disease, Nasu-Hakola disease, or multiple sclerosis.

公开(公告)号：US12258398B2

公开(公告)日：2025-03-25

申请号：US17263534

申请日：2019-07-26

Applicant: Alector LLC

Inventor： Patricia Culp ,  Rashmi Bankoti ,  Helen Lam ,  Arnon Rosenthal

IPC: C07K16/28 ,  A61K39/00 ,  A61K47/68 ,  A61P35/00

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a Siglec-5 protein, e.g., human Siglec-5, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

公开(公告)号：US20250026827A1

公开(公告)日：2025-01-23

申请号：US18756198

申请日：2024-06-27

Applicant: Alector LLC

Inventor： Andrew Pincetic ,  Patricia Culp ,  Arnon Rosenthal

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a SIRPβ1 polypeptide, e.g., a human SIRPβ1, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

公开(公告)号：US12186409B2

公开(公告)日：2025-01-07

申请号：US17088237

申请日：2020-11-03

Applicant: Alector LLC

Inventor： Arnon Rosenthal ,  Tina Schwabe

IPC: G01N33/543 ,  A61K49/00 ,  C07K16/28 ,  G01N21/64 ,  G01N33/533 ,  G01N33/542

Abstract: The present disclosure provides methods of screening for a sortilin binding antagonist. In some embodiments, the methods include incubating an agent with a sortilin protein and a sortilin ligand, where the sortilin protein and sortilin ligand are each attached to a member of a fluorescence donor/acceptor pair, exciting the fluorescence donor of the fluorescence donor/acceptor pair, and detecting fluorescence emitted by the fluorescence donor at a second wavelength and fluorescence emitted by the fluorescence acceptor at a third wavelength. A decrease in the ratio of the fluorescence emitted by the fluorescence acceptor at the third wavelength to the fluorescence emitted by the fluorescence donor at the second wavelength, as compared to the ratio in the absence of the agent, indicates that the agent is a sortilin binding antagonist.

公开(公告)号：US20240383997A1

公开(公告)日：2024-11-21

申请号：US18621575

申请日：2024-03-29

Applicant: ALECTOR LLC

Inventor： Eric BROWN ,  Hamid SALIMI ,  Wei-Hsien HO ,  Leonard PRESTA ,  Margaret TANG ,  Jeonghoon SUN

IPC: C07K16/28 ,  A61K49/00 ,  C07K16/18 ,  G01N33/50

Abstract: Provided herein are engineered constant domains that have been engineered to comprise a blood brain barrier (BBB)-binding region, such a CDRH3 from an antibody that binds to a blood brain barrier target. Such engineered constant domains can be within a full length antibody or an antigen-binding fragment of an antibody such that the antibody or fragment is capable of binding to both the antigen of the antibody or fragment and the BBB target and is capable of being transported across the BBB.

公开(公告)号：US20230312712A1

公开(公告)日：2023-10-05

申请号：US18174499

申请日：2023-02-24

Applicant: Alector LLC

Inventor： Tina SCHWABE ,  Eric BROWN ,  Philip KONG ,  Ilaria TASSI ,  Seung-Joo LEE ,  Arnon ROSENTHAL ,  Robert PEJCHAL ,  Nels P. NIELSON

IPC: C07K16/28 ,  A61P25/28

CPC classification number: C07K16/2803 ,  A61P25/28 ,  C07K2317/71 ,  C07K2317/90 ,  C07K2317/75 ,  C07K2317/76 ,  A61K2039/505

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 or human TREM2, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

公开(公告)号：US20230303681A1

公开(公告)日：2023-09-28

申请号：US17820686

申请日：2022-08-18

Applicant: ALECTOR LLC

Inventor： Arnon ROSENTHAL ,  Eric BROWN ,  Tina SCHWABE ,  Angie YEE ,  Herve RHINN

IPC: C07K16/28

CPC classification number: C07K16/28 ,  C07K2317/34 ,  C07K2317/56

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal antibodies, antibody fragments, etc., that specifically bind a TMEM106B polypeptide, e.g., a mammalian TMEM106B or human TMEM106B, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

公开(公告)号：US11667710B2

公开(公告)日：2023-06-06

申请号：US17016744

申请日：2020-09-10

Applicant: Alector LLC

Inventor： Arnon Rosenthal ,  Kate Monroe ,  Seung-Joo Lee

IPC: C07K16/28 ,  G01N33/577 ,  G01N33/574 ,  A61P31/04 ,  A61P25/00 ,  A61P29/00 ,  A61P35/00 ,  A61K39/395 ,  A61K45/06 ,  A61K39/00

CPC classification number: C07K16/2803 ,  A61K39/3955 ,  A61K45/06 ,  A61P25/00 ,  A61P29/00 ,  A61P31/04 ,  A61P35/00 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/30 ,  C07K2317/34 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  G01N33/574 ,  G01N33/577

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a Siglec-9 protein, e.g., human Siglec-9 or a mammalian Siglec-9, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

公开(公告)号：US20230142579A1

公开(公告)日：2023-05-11

申请号：US17821010

申请日：2022-08-19

Applicant: Alector LLC

Inventor： Philip KONG ,  Herve RHINN ,  Tina SCHWABE ,  Angie YEE ,  Ilaria TASSI ,  Muhammad Abbas ALHAWAGRI ,  Arnon ROSENTHAL

IPC: C07K16/28

CPC classification number: C07K16/28 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/71

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a MS4A4A polypeptide, e.g., a mammalian MS4A4A or human MS4A4A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.